172 related articles for article (PubMed ID: 15650881)
1. Ile118Val genetic polymorphism of CYP3A4 and its effects on lipid-lowering efficacy of simvastatin in Chinese hyperlipidemic patients.
Wang A; Yu BN; Luo CH; Tan ZR; Zhou G; Wang LS; Zhang W; Li Z; Liu J; Zhou HH
Eur J Clin Pharmacol; 2005 Feb; 60(12):843-8. PubMed ID: 15650881
[TBL] [Abstract][Full Text] [Related]
2. Lack of association between SLCO1B1 polymorphism and the lipid-lowering effects of atorvastatin and simvastatin in Chinese individuals.
Fu Q; Li YP; Gao Y; Yang SH; Lu PQ; Jia M; Zhang LR
Eur J Clin Pharmacol; 2013 Jun; 69(6):1269-74. PubMed ID: 23263738
[TBL] [Abstract][Full Text] [Related]
3. CYP3A4*1G polymorphism is associated with lipid-lowering efficacy of atorvastatin but not of simvastatin.
Gao Y; Zhang LR; Fu Q
Eur J Clin Pharmacol; 2008 Sep; 64(9):877-82. PubMed ID: 18528690
[TBL] [Abstract][Full Text] [Related]
4. CYP3AP1*3 allele is associated with lipid-lowering efficacy of simvastatin and atorvastatin in Chinese women.
Li YP; Zhang LR; Jia M; Hu XJ
J Clin Pharmacol; 2011 Feb; 51(2):181-8. PubMed ID: 20519697
[TBL] [Abstract][Full Text] [Related]
5. Novel mutations of CYP3A4 in Chinese.
Hsieh KP; Lin YY; Cheng CL; Lai ML; Lin MS; Siest JP; Huang JD
Drug Metab Dispos; 2001 Mar; 29(3):268-73. PubMed ID: 11181494
[TBL] [Abstract][Full Text] [Related]
6. The role of common variants of ABCB1, CYP3A4, and CYP3A5 genes in lipid-lowering efficacy and safety of simvastatin treatment.
Fiegenbaum M; da Silveira FR; Van der Sand CR; Van der Sand LC; Ferreira ME; Pires RC; Hutz MH
Clin Pharmacol Ther; 2005 Nov; 78(5):551-8. PubMed ID: 16321621
[TBL] [Abstract][Full Text] [Related]
7. Associations between the genotypes and phenotype of CYP3A and the lipid response to simvastatin in Chinese patients with hypercholesterolemia.
Hu M; Mak VW; Xiao Y; Tomlinson B
Pharmacogenomics; 2013 Jan; 14(1):25-34. PubMed ID: 23252946
[TBL] [Abstract][Full Text] [Related]
8. Novel CYP3A4 intron 6 single nucleotide polymorphism is associated with simvastatin-mediated cholesterol reduction in the Rotterdam Study.
Elens L; Becker ML; Haufroid V; Hofman A; Visser LE; Uitterlinden AG; Stricker BCh; van Schaik RH
Pharmacogenet Genomics; 2011 Dec; 21(12):861-6. PubMed ID: 21946898
[TBL] [Abstract][Full Text] [Related]
9. The influence of apolipoprotein B and E gene polymorphisms on the response to simvastatin therapy in patients with hyperlipidemia.
Ye P; Shang Y; Ding X
Chin Med Sci J; 2003 Mar; 18(1):9-13. PubMed ID: 12901521
[TBL] [Abstract][Full Text] [Related]
10. Influence of genetic variation in CYP3A4 and ABCB1 on dose decrease or switching during simvastatin and atorvastatin therapy.
Becker ML; Visser LE; van Schaik RH; Hofman A; Uitterlinden AG; Stricker BH
Pharmacoepidemiol Drug Saf; 2010 Jan; 19(1):75-81. PubMed ID: 19802823
[TBL] [Abstract][Full Text] [Related]
11. CYP2C9 Genetic Polymorphism is a Potential Predictive Marker for the Efficacy of Rosuvastatin Therapy.
Lin J; Zhang Y; Zhou H; Wang X; Wang W
Clin Lab; 2015; 61(9):1317-24. PubMed ID: 26554252
[TBL] [Abstract][Full Text] [Related]
12. Effect of Cytochrome P450 7A1 (CYP7A1) Polymorphism on Lipid Responses to Simvastatin Treatment.
Liu N; Yang G; Liu Y; Hu M; Cai Y; Hu Z; Jia C; Zhang M
J Cardiovasc Pharmacol; 2020 Feb; 75(2):168-173. PubMed ID: 31663874
[TBL] [Abstract][Full Text] [Related]
13. Interactions between CYP3A5*3 and POR*28 polymorphisms and lipid lowering response with atorvastatin.
Wei KK; Zhang LR
Clin Drug Investig; 2015 Sep; 35(9):583-91. PubMed ID: 26293521
[TBL] [Abstract][Full Text] [Related]
14. Impact of matrix metalloproteinase 9 rs3918242 genetic variant on lipid-lowering efficacy of simvastatin therapy in Chinese patients with coronary heart disease.
Xu Y; Wang Y; Zhi J; Qi L; Zhang T; Li X
BMC Pharmacol Toxicol; 2017 Apr; 18(1):28. PubMed ID: 28390432
[TBL] [Abstract][Full Text] [Related]
15. No effect of CYP3A4 intron 6 C>T polymorphism (CYP3A4*22) on lipid-lowering response to statins in Greek patients with primary hypercholesterolemia.
Ragia G; Kolovou V; Tavridou A; Elens L; Tselepis AD; Elisaf M; Van Schaik RH; Kolovou G; Manolopoulos VG
Drug Metab Pers Ther; 2015 Mar; 30(1):43-8. PubMed ID: 25274942
[TBL] [Abstract][Full Text] [Related]
16. Association of cytochromes P450 3A4*22 and 3A5*3 genotypes and polymorphism with response to simvastatin in hypercholesterolemia patients.
Elalem EG; Jelani M; Khedr A; Ahmad A; Alaama TY; Alaama MN; Al-Kreathy HM; Damanhouri ZA
PLoS One; 2022; 17(7):e0260824. PubMed ID: 35839255
[TBL] [Abstract][Full Text] [Related]
17. Statin therapy correlated CYP2D6 gene polymorphism and hyperlipidemia.
Li J; Wang X; Zhang Z; Zou J; Chen Y; Wang X; Wu J
Curr Med Res Opin; 2014 Feb; 30(2):223-8. PubMed ID: 24156754
[TBL] [Abstract][Full Text] [Related]
18. Effect of simvastatin on plasma homocysteine levels and its modification by MTHFR C677T polymorphism in Chinese patients with primary hyperlipidemia.
Jiang S; Chen Q; Venners SA; Zhong G; Hsu YH; Xing H; Wang X; Xu X
Cardiovasc Ther; 2013 Aug; 31(4):e27-33. PubMed ID: 23865383
[TBL] [Abstract][Full Text] [Related]
19. Effects of simvastatin on C-reactive protein in mixed hyperlipidemic and hypertriglyceridemic patients.
Bays HE; Stein EA; Shah AK; Maccubbin DL; Mitchel YB; Mercuri M
Am J Cardiol; 2002 Nov; 90(9):942-6. PubMed ID: 12398959
[TBL] [Abstract][Full Text] [Related]
20. Interactions between CYP7A1 A-204C and ABCG8 C1199A polymorphisms on lipid lowering with atorvastatin.
Wei KK; Zhang LR; Zhang Y; Hu XJ
J Clin Pharm Ther; 2011 Dec; 36(6):725-33. PubMed ID: 21128988
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
